THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of Evenity™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for